Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2016 | Research

Effect of a chemical inhibitor of human phosphatidylethanolamine-binding protein 4 on radiosensitivity of rectal cancer cells

Authors: Jianming Qiu, Yong Tao, Guangen Yang, Kan Xu, A. Li Lin, Liuyu Li

Published in: World Journal of Surgical Oncology | Issue 1/2016

Abstract

Background

Human phosphatidylethanolamine-binding protein 4 (hPEBP4) is a well-established antiapoptosis molecule in recent years. It has also been demonstrated to be involved in the radioresistance of rectal cancer. The objective of this study was to determine whether IOI-42, a chemical inhibitor of hPEBP4, could sensitize rectal cancer cells.

Methods

Rectal cancer cells were treated with IOI-42 alone or in combination with irradiation. Clonogenic survival assays and tumor volume growth analysis were used, respectively, to study the effect of IOI-42 in vitro and in vivo. Western blot was adopted to measure the activation of signal pathway.

Results

Clonogenic survival assays showed that IOI-42, combined with irradiation, caused a significant decrease in colony formation compared with radiation alone, which was associated with the downregulation of Akt activation. And we also confirmed the effect of IOI-42 in nude mice transplanted with human rectal cancer subcutaneously.

Conclusions

These data suggest that IOI-42 has a potential to enhance the radiosensitivity of rectal cancer cells, providing a rationale to further investigate the feasibility of combining of IOI-42 with radiation, keeping in mind that this may result in unexpected toxicities.

Bradley D, Ratcliffe O, Vincent C, et al. Inflorescence commitment and architecture in Arabidopsis. Science. 1997;275:80–3.CrossRefPubMed

Hengst U, Albrecht H, Hess D, Monard D. The phosphatidylethanolamine-binding protein is the prototype of a novel family of serine protease inhibitors. J Biol Chem. 2001;276:535–40.CrossRefPubMed

Wang X, Li N, Liu B, Sun H, Chen T, et al. A novel human phosphatidylethanolamine-binding protein resists tumor necrosis factor alpha induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization. J Biol Chem. 2004;279:45855–64.CrossRefPubMed

Qiu J, Yang G, Shen Z, Xie Y, Wang L. hPEBP4 as a predictive marker for the pathological response of rectal cancer to preoperative radiotherapy. Int J Colorectal Dis. 2013;28:241–6.CrossRefPubMed

Qiu J, Yang G, Lin A, Shen Z, Wang D, Ding L. Human phosphatidylethanolamine-binding protein 4 promoted the radioresistance of human rectal cancer by activating Akt in an ROS-dependent way. PLoS One. 2014;9(3):e90062.CrossRefPubMedPubMedCentral

Wang X, Li N, Li H, Liu B, Qiu J, et al. Silencing of human phosphatidylethanolamine-binding protein 4 sensitizes breast cancer cells to TNF-a-induced apoptosis and cell growth arrest. Clin Cancer Res. 2005;11:7545–53.CrossRefPubMed

Li H, Wang X, Li N, Qiu J, Zhang Y, et al. hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways. J Biol Chem. 2007;282:4943–50.CrossRefPubMed

Li P, Wang X, Li N, Kong H, Guo Z, et al. Anti-apoptotic hPEBP4 silencing promotes TRAIL-induced apoptosis of human ovarian cancer cells by activating ERK and JNK pathways. Int J Mol Med. 2006;18:505–10.PubMed

Zhang Y, Wang X, Xiang Z, Li H, Qiu J, et al. Promotion of cellular migration and apoptosis resistance by a mouse eye-specific phosphatidylethanolamine-binding protein. Int J Mol Med. 2007;19:55–63.PubMed

10.

Qiu J, Xiao J, Han C, Li N, Shen X, Jiang H, Cao X. Potentiation of tumor necrosis factor-alpha-induced tumor cell apoptosis by a small molecule inhibitor for anti-apoptotic protein hPEBP4. J Biol Chem. 2010;285(16):12241–7.CrossRefPubMedPubMedCentral

11.

Lacher MD, Tiirikainen MI, Saunier EF, Christian C, Anders M, et al. Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus receptor in conjunction with reversal of epithelial-mesenchymal transition. Cancer Res. 2006;66:1648–57.CrossRefPubMed

12.

Wildeman MA, Gibcus JH, Hauptmann M, Begg AC, van Velthuysen ML, Hoebers FJ, Mastik MF, Schuuring E, van der Wal JE, van den Brekel MW. Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response? Laryngoscope. 2009;119:316–22.CrossRefPubMed

13.

Khor LY, Moughan J, Al-Saleem T, Hammond EH, Venkatesan V, Rosenthal SA, Ritter MA, Sandler HM, Hanks GE, Shipley WU, Pollack A. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin Cancer Res. 2007;13:3585–90.CrossRefPubMedPubMedCentral

14.

Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Kawamoto A, Yasuda H, Morimoto Y, Fujikawa H, Inoue Y, Miki C, Kusunoki M. Immunohistochemical features of CD133 expression: association with resistance to chemoradiotherapy in rectal cancer. Oncol Rep. 2010;24:345–50.CrossRefPubMed

15.

Smith L, Qutob O, Watson MB, Beavis AW, Potts D, Welham KJ, Garimella V, Lind MJ, Drew PJ, Cawkwell L. Proteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome? Neoplasia. 2009;11:1194–207.CrossRefPubMedPubMedCentral

16.

Fu TJ, Pcng J, Lee G, et al. Cyclin K functions as a CDK9 regulatory subunit and participates in RNA polymerase transcription. J Biol Chem. 1999;274:34527–30.CrossRefPubMed

17.

Singleton BK, Pricstlcy A, Steingrimsdottir H, et al. Molecular and biochemical characterization of xrs mutants defective in Ku80. Mol Ccll Biol. 1997;17:1264–73.CrossRef

18.

Bussing CH, Alt FW. The cellular response to general and programmed DNA double strand breaks. DNA Repair (Amst). 2004;3:781–96.CrossRef

19.

Xic S, Shun XF, Shang K, et al. Relevance of LIG4 gene polymorphisms with cancer susceptibility: evidence from meta-analysis. Sci Rcp. 2014;4:6630.

20.

Thackcr J, Zdzicnicka MZ. The XRCC gene: expanding role in DNA double-strand break repair. DNA Repair (Amst). 2004;3:1081–90.CrossRef

Title: Effect of a chemical inhibitor of human phosphatidylethanolamine-binding protein 4 on radiosensitivity of rectal cancer cells
Authors: Jianming Qiu
Yong Tao
Guangen Yang
Kan Xu
A. Li Lin
Liuyu Li
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2016
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-016-0977-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effect of a chemical inhibitor of human phosphatidylethanolamine-binding protein 4 on radiosensitivity of rectal cancer cells

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Role of prophylactic central compartment lymph node dissection in clinically N0 differentiated thyroid cancer patients: analysis of risk factors and review of modern trends

Newly designed retentive posts of mandibular reconstruction plate in oral cancer patients based on preliminary FEM study

Gastric biomarkers: a global review

Number of evaluated lymph nodes and positive lymph nodes, lymph node ratio, and log odds evaluation in early-stage pancreatic ductal adenocarcinoma: numerology or valid indicators of patient outcome?

Decreased miR-198 expression and its prognostic significance in human gastric cancer

Transpapillary biliary biopsy for malignant biliary strictures: comparison between cholangiocarcinoma and pancreatic cancer